Meridian buys Gull at lower price:
This article was originally published in Clinica
Meridian Diagnostics is to buy Fresenius subsidiary Gull Laboratories for $2.25 a share, down from $3 per share which was discussed when the deal was first announced in July. As a result of the deal, which is worth around $19 million, Gull will become a wholly-owned subsidiary of Cincinnati, Ohio-based Meridian. Meridian lowered its original offer earlier this month, basing its new offer on Gull's second-quarter results. Gull, of Salt Lake City, Utah, manufactures tests for the detection of infectious diseases and autoimmune disorders.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.